There was a double whammy of good news involving Dechra, the international veterinary pharmaceuticals business based in our Pavilions. Not only has the company now expanded to occupy all three wings of the Pavilions, it also announced another stunning set of results for the year ending June 30, 2018.
Acquisitions in the Netherlands and New Zealand coupled with new product registrations and outperformance in the majority of countries and therapeutic sectors helped push revenues to £407.1 million – a jump of 13% on the previous 12 months.
Bosses said its people strategy remained important to the success of the group – instigating numerous initiatives within the year, including ongoing leadership and management development programmes, several apprenticeship schemes as well as offering ongoing training across all levels of employment.
The report added: “We have also launched wellness and wellbeing initiatives and have had an independent company conduct an employee engagement survey which was completed by 87% of all Group staff with the vast majority stating that Dechra is a great place to work.
“We would not be able to achieve anything without the commitment, hard work and dedication of our team and we would like to thank all employees for their contribution to the ongoing success of the business.”
The Group said that while Brexit was causing some market volatility, it had engaged in contingency planning and is implementing a hard Brexit mitigation plan.
“We expect the financial impact to be immaterial. Our business is naturally hedged and diversified, which helps in a period of economic uncertainty and exchange rate volatility.”
James Thompson, MD of Sansaw Estate, said he was delighted to see Dechra go from strength to strength.
“It is fabulous to have such an innovative and progressive business on the Estate,” he explained. “Dechra really is at the top of its field and we are delighted it has chosen to make Sansaw its home for the coming years.”